Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NOF Corporation is a prominent Japanese chemical company that has become a global leader in the life sciences industry through its advanced drug delivery system (DDS) technologies. The company is renowned for its SUNBRIGHT series, which provides high-purity PEG derivatives for the PEGylation of biopharmaceuticals, enhancing their stability and reducing immunogenicity. NOF also plays a critical role in the field of genetic medicine with its COATSOME series, offering specialized lipids and ionizable lipids essential for the formulation of lipid nanoparticles (LNPs) used in mRNA vaccines and gene therapies. Additionally, the company produces biocompatible MPC polymers for medical devices and high-grade pharmaceutical excipients. As a key supplier and CDMO, NOF supports a wide range of modalities including proteins, peptides, and nucleic acids for global pharmaceutical partners.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NOF Corporation.